دورية أكاديمية

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

التفاصيل البيبلوغرافية
العنوان: Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
المؤلفون: Motzer, Robert J, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Alekseev, Boris, Rha, Sun Young, Merchan, Jaime, Goh, Jeffrey C, Lalani, Aly-Khan A, De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Méndez-Vidal, María José, Kopyltsov, Evgeny, Tjulandin, Sergei, Gordoa, Teresa Alonso, Kozlov, Vadim, Alyasova, Anna, Winquist, Eric, Maroto, Pablo, Kim, Miso, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Rodriguez-Lopez, Karla, Burgents, Joseph, He, Cixin, Okpara, Chinyere E, McKenzie, Jodi, Choueiri, Toni K, Galamaga, Rob
المصدر: ENT and Skull Base Surgery
بيانات النشر: Barrow - St. Joseph's Scholarly Commons
سنة النشر: 2024
نوع الوثيقة: text
اللغة: unknown
العلاقة: https://scholar.barrowneuro.org/ent-and-skull-base-surgery/21Test
DOI: 10.1200/JCO.23.01569
الإتاحة: https://doi.org/10.1200/JCO.23.01569Test
https://scholar.barrowneuro.org/ent-and-skull-base-surgery/21Test
رقم الانضمام: edsbas.E7F6A072
قاعدة البيانات: BASE